🇺🇸 GILD — Gilead Sciences, Inc.

Salud Compra
← Volver

Precio actual

166,89 USD

Máx. histórico

174,48

2 días

Split 2:1 del 28/01/2013

Caída desde máximo

-4,35%

Rango 52 semanas

116,88 – 176,58

Variación hoy

-0,41%

Cierre anterior

167,57

Rango de hoy

164,00 – 169,06

Volumen hoy

5.695.172

Peor caída histórica

-70,83%

27/01/1992 → 06/06/1994

Recuperado en 431 días

Volatilidad anualizada ⓘ

46,20%

Información
Nombre completo
Gilead Sciences, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
17.000
PER ⓘ
—
Dividend yield
1,96% (puede no estar actualizado)
Precio objetivo analistas
172,50 USD (puede no estar actualizado)
Primera cotización
22/01/1992
Precio actualizado
hace 1 día
Sobre la empresa

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Dividendos repartidos Total últimos 12 meses: 3,2500 USD · Yield: 1,95%
Fecha de pago Importe por participación
15/09/2026 0,8200 USD
15/06/2026 0,8200 USD
13/03/2026 0,8200 USD
15/12/2025 0,7900 USD
15/09/2025 0,7900 USD
13/06/2025 0,7900 USD
14/03/2025 0,7900 USD
13/12/2024 0,7700 USD
13/09/2024 0,7700 USD
14/06/2024 0,7700 USD
14/03/2024 0,7700 USD
14/12/2023 0,7500 USD
14/09/2023 0,7500 USD
14/06/2023 0,7500 USD
14/03/2023 0,7500 USD
Splits Registrados en el histórico de precios
Fecha Ratio
28/01/2013 2:1
25/06/2007 2:1
07/09/2004 2:1
08/03/2002 2:1
22/02/2001 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/02/2016 86,50 88,45 86,01 87,36 -0,50% 2,82% 13.013.400
10/02/2016 88,69 89,85 87,54 87,80 +0,63% 2,60% 13.462.300
09/02/2016 84,20 88,48 84,10 87,25 +2,33% 5,20% 14.322.700
08/02/2016 84,19 86,65 83,86 85,26 +0,14% 3,31% 19.111.300
05/02/2016 86,68 88,02 84,45 85,14 -1,78% 4,12% 15.732.800
04/02/2016 86,02 87,45 85,61 86,68 +0,34% 2,14% 14.538.700
03/02/2016 84,91 86,99 83,87 86,39 +4,45% 3,67% 24.497.700
02/02/2016 84,18 84,22 81,89 82,71 -1,59% 2,77% 16.895.600
01/02/2016 82,32 84,52 82,28 84,05 +1,27% 2,72% 17.943.600
29/01/2016 84,28 85,30 82,33 83,00 -5,18% 3,52% 37.029.000
28/01/2016 90,00 90,22 86,86 87,53 -2,34% 3,73% 14.168.300
27/01/2016 91,84 92,10 89,00 89,63 -2,80% 3,38% 12.520.300
26/01/2016 90,72 92,83 90,25 92,21 +1,77% 2,84% 6.889.200
25/01/2016 91,53 93,54 90,43 90,61 -1,33% 3,40% 10.188.400
22/01/2016 90,40 92,07 89,71 91,83 +3,33% 2,61% 9.160.700
21/01/2016 90,37 90,60 88,71 88,87 -1,86% 2,09% 12.158.300
20/01/2016 88,00 91,83 86,28 90,55 +0,72% 6,31% 19.676.300
19/01/2016 93,14 93,22 88,85 89,90 -2,11% 4,69% 14.373.700
15/01/2016 90,37 92,78 89,68 91,84 -1,27% 3,43% 18.108.300
14/01/2016 92,72 94,88 90,79 93,02 +0,52% 4,41% 16.303.200
13/01/2016 97,25 98,03 92,12 92,54 -4,70% 6,08% 12.135.700
12/01/2016 96,90 98,49 95,21 97,10 +0,62% 3,38% 9.830.100
11/01/2016 97,22 97,22 94,29 96,50 +0,05% 3,01% 12.322.500
08/01/2016 96,90 97,99 96,41 96,45 +0,21% 1,63% 11.976.000
07/01/2016 98,06 99,00 96,03 96,25 -4,04% 3,03% 12.944.600
06/01/2016 97,57 100,68 97,52 100,30 +1,05% 3,24% 12.540.700
05/01/2016 99,69 99,85 98,70 99,26 +1,28% 1,15% 9.260.800
04/01/2016 99,77 100,00 97,01 98,01 -3,14% 3,00% 14.904.400
31/12/2015 102,36 102,42 101,17 101,19 -0,95% 1,22% 6.245.200
30/12/2015 102,84 103,05 102,03 102,16 -1,16% 0,99% 4.876.300